

## Subject Index, 1978

Vol. 28, Nos. 1-6

### A

#### **Acid phosphatase** determination

For hairy cell leukemia, 270, 272, 274-275  
For prostate cancer,  
Correlation with advanced disease, 258-260  
Measurement techniques of, 106, 258-260  
CIEP, 107-108, 260-262  
RIA, 106-107, 260-262  
Solid-phase fluorescent immunoassay,  
262-263  
Variations in, 259-260

#### **Actinomycin D**

For embryonal rhabdomyosarcoma, 159  
For Wilms' tumor, 148-151

#### **Adenocarcinoma**, of the colon, 181

#### **Adrenalectomy**

For metastatic breast cancer, 192  
For prostate cancer, 112

#### **Adriamycin**

For bladder cancer, 175  
For soft tissue sarcomas, 292-294  
Embryonal rhabdomyosarcoma, 159

#### **Alkaline phosphatase** determination

For Paget's disease, 178

#### **American Cancer Society**

Conference on Human Values and  
Cancer, 63-64  
National Prostatic Cancer Task  
Force, 105, 261  
Rehabilitation programs of, 320  
Role in Papanicolaou stamp, 164-169  
Study of cancer in the elderly, 6  
Study of death rates in smokers of low tar  
and nicotine cigarettes, 375-376

#### **Anorexia**, and cancer, 194-195, 198, 322, 326

#### **Antiemetics**

Continuous infusion of,  
By transdermal drug delivery, 351-352  
For nausea and vomiting, 194-195  
Clinical trials of, 198  
FDA approved, 200  
Placebo effects of, 195  
Side effects of, 196, 200

#### **APUD** mechanism, 75

#### **Asbestos-associated disease**, in shipyard workers

Groton, Connecticut study of, 92-94  
Latency period of, 87-91, 94  
Mesothelioma, 87-90  
Recommendations for, 94-95, 98  
Risk of, 87-97  
X-ray abnormalities in, 92-94, 97-99

### B

#### **Benign lesions** that mimic cancer

Examples of, 339-340

#### **Biography**, of

Dukes, Cuthbert E., 247-248

Jones, Henry Bence, 47-48

Loeb, Leo, 367-368

Rhoads, Cornelius P., 304-305

Taylor, Robert M., 127-128

#### **Biopsy**

Bone marrow,  
For chronic lymphocytic leukemia, 272  
For hairy cell leukemia,  
268-270, 274-275  
For soft tissue sarcomas, 285  
Liver,  
For chronic lymphocytic leukemia, 273  
For hairy cell leukemia, 270

#### **Bladder cancer**

Cigarette smoking and, 60  
Diagnosis of, 170  
Following exposure to,  
Phenyl-beta-naphthylamine, 116  
Saccharin, 362  
In situ, 172, 174  
In the elderly, 6  
Pathologic vs. clinical staging of, 172-173  
Treatment of, 172-176

#### **Blood-brain-barrier**

Role in vomiting, 195

#### **Bone cancer**

Improvement in survival for, 319  
In the elderly, 6  
(See also, Osteogenic sarcoma)

#### **Breast cancer**

Clinical trials of, 242, 244, 246  
Correlation with endocrine profiles, 61  
Diagnosis of minimal cancer, 141-145  
In breast cancer detection demonstration  
projects, 141-142  
Effects of orchectomy on, 182-190  
Estrogen receptors and, 62, 191  
Following oral contraceptives, 118-119  
In the elderly, 4-6  
Reconstruction following mastectomy  
for, 218-224  
Relationship with thyroid cancer, 81-84  
Risk of developing, 43  
Self-examination for, 319  
(See also, Nipple discharge)

### C

#### **Cancer**

Analysis of progress and cures,  
In 1926, 317-318  
In 1978, 318-320  
In the elderly,  
Incidence rates of, 3-4, 6  
Mortality rates of, 2-3, 5-6  
Accuracy of, 2, 6  
(See also, by site)

#### **Carcinogens**

Asbestos, 87-99  
Association with chemotherapy, 57-59  
Chemical, 58, 124  
Cigarette smoke, 60, 95, 240, 375-376  
In the environment, 124-126  
Iodine in thyroid cancer, 76-77  
Role of government, 239-240, 313-314  
Saccharin, 362

**Catecholamines**

Excretion in neuroblastoma, 152

**Chemoreceptor trigger zone (CTZ)**

Vomiting and, 194-196, 198

**Chemotherapy, cancer**

ABVD regimen, 116

Actinomycin D,

For embryonal rhabdomyosarcoma, 159

For Wilms' tumor, 148-151

Adriamycin,

For bladder cancer, 175

For embryonal rhabdomyosarcoma, 159

For soft tissue sarcomas, 292-294

Advocacy of Dr. Rhoads in, 304-305

Ara-C,

By continuous infusion, 344

Combination,

For soft tissue sarcomas, 159, 292-294

Cyclophosphamide,

For embryonal rhabdomyosarcoma, 159

For neuroblastoma, 155

For bladder cancer, 173, 175

For hairy cell leukemia, 276-277

For Hodgkin's disease, 116-117

For neuroblastoma, 155

For prostate cancer, 112-114

For soft tissue sarcomas, 159, 292-294

For Wilms' tumor, 148-151

5-FU,

Increased tolerance for,

Following intravenous

hyperalimentation, 349

Intravenous hyperalimentation as

adjunct to, 324-326

Methotrexate,

For synovial sarcoma, 162

MOPP program, 117

Nausea and vomiting following,

194-195, 324

Nitrogen mustards, 306-312

Oncologic potential of, 57-59

Rubidazone, 62

Vincristine,

For neuroblastoma, 155

For soft tissue sarcomas, 159, 292-294

For Wilms' tumor, 148-151

(See also, Drug delivery systems)

**Childhood Cancer**

Hodgkin's disease, 116-117

Incidence of, 23

Leukemia,

Effects of chemotherapy and, 57-59

(See also, Wilms' tumor, Neuroblastoma, and Sarcomas)

**Classics in Oncology**

Dukes' pathologic staging of rectal cancer, 249-255

Effects of orchiectomy on breast cancer, 182-190

First description of Bence-Jones protein, 49-56

Loeb on the transplantation of tumors, 369-374

Rhoads evaluation of nitrogen mustards, 306-312

(See also, Biography)

**Classification, general**

Dukes' pathologic,

of rectal cancer, 249-255

Of bladder cancer, 171

Of prostate cancer, 106-109

Of thyroid cancer, 70

Of Wilms' tumor, 148

**Clinical trials**

Ethical questions concerning, 241, 243

For bladder cancer, 175

For prostate cancer, 112-114

And CIEP determinations of, 260-261

And solid-phase fluorescent immunoassay of, 262-263

Government regulation of, 244

Misconceptions concerning, 241-244, 246

Of antiemetics, 198

Of National Surgical Adjuvant Breast Cancer Project Protocol, 242, 245

Preferred length of, 245, 246

**Colon and rectum cancer**

Dukes' staging of, 249-255

Diagnosis of, 206-207

By guaiac testing, 205-207, 319

By sigmoidoscopy, 202-210

(See also, Colorectal polyps)

**Colorectal polyps**

Detection of, 207-208, 211-215

Development of carcinoma in, 214, 335-336

In males,

According to age, 213-217

Incidence of, 211-217

**Complications, of cancer therapy**

Fistulas, 327-328

Infection, 272, 274, 276, 323, 329

Malnutrition, 322-323

Nausea and vomiting, 194-201, 324

Necrosis, 287

Radiation enteritis, 326

**Computerized transaxial tomography (CT scan)**

Applications for, 100-101

Exposure to radiation and, 238

For childhood cancers, 147, 149, 154, 158

For prostate cancer, 108-109

Government regulation of, 102-103

Improvements in, 101-102

Limitations of, 102-103

**Connecticut Tumor Registry**

Incidence of thyroid cancer in, 66, 68-69, 78-79

**Contraceptive pills, and cancer**

(See, Oral contraceptives)

**Counter-immunolectrophoresis (CIE)**

For prostatic acid phosphatase, 107-108, 260-262

**Cytology**

For bladder cancer, 170

For hairy cell leukemia, 266-270, 272-274

Nipple discharge and role of, 134

**Cyclophosphamide**

For embryonal rhabdomyosarcoma, 159

For neuroblastoma, 155

## **Cystectomy**

For bladder cancer, 170-176  
For embryonal rhabdomyosarcoma, 160-161

## **Diagnosis, cancer**

Of bladder cancer, 170  
Of colon and rectum cancer, 206-207  
Of hairy cell leukemia, 265-274  
Of minimal cancer, 141-145  
Of neuroblastoma, 152-154  
Of soft tissue sarcomas, 285-287  
Embryonal rhabdomyosarcoma, 158-159  
Fibroma, 161-162  
Synovial sarcoma, 162  
Of Wilms' tumor, 146-148  
With CT scan, 100-102  
With proctosigmoidoscopy, 202-217

## **DNA**

Molecular hybridization, 61

## **Drug delivery systems**

Continuous, prolonged intravenous therapy, 343  
Definition of, 343  
New techniques for, 349-353  
Rationale for,  
Cell kinetics, 345-349  
Pharmacokinetics, 344-345  
Toxicity, 349

## **Dukes, Cuthbert, E.**

Biography of, 247-248

## **E**

## **Editorials**

Human values and cancer, 63-64  
No "safe" cigarette, 375-376  
Tribute to Robert M. Taylor, M.D., 127-128  
Telling the patient the truth, 256

## **Electron microscopy**

For chronic lymphocytic leukemia, 272  
For hairy cell leukemia, 270, 273-275

## **Emotional needs of cancer**

patients, 63-64, 256  
(See also, Hospice approach)

## **En bloc excision**

Of major ducts in breast, 132-139, 296

## **Endocrine therapy**

Adrenalectomy,  
For prostate cancer, 112  
For breast cancer, 62, 191-192  
For prostate cancer, 110-111  
Hypophysectomy,  
For prostate cancer, 112  
(See also, Estrogens)

## **Endometrial cancer**

And oral contraceptives, 120-121

## **Enzymes**

(See, Acid phosphatase determinations)

## **Embryonal rhabdomyosarcomas**

Evaluation of, 158  
Management of, 159-161  
Sites of, 157

## **Epidemiology**

Cancer in the elderly, 2-6  
Of bladder cancer, 170  
Of prostate cancer, 104  
Of thyroid cancer, 66-86  
Risk of developing cancer, 33-46  
Role of asbestos, 87-99

## **Erythroplasia**

And oral cancer, 299-302

## **Estrogens**

And oral contraceptives, 120, 122  
For metastatic breast cancer, 192

## **Estrogen receptors**

For breast cancer,  
Correlation to prognosis of, 62  
For prostate cancer, 109  
Role in endocrine therapy, 191

## **Experimental tumors**

Effects of intravenous hyperalimentation on, 322-323  
In AKR mice, 280-281  
Of the breast, 83  
Of the thyroid, 74-76, 79  
Transplantation of, 369-374

## **F**

## **FDA**

Delaney Clause of, 240  
Role in determining carcinogens, 125-126

## **Fibrosarcoma**

161-162  
(See also, Fistulas, radiation-related)

## **G**

## **Genetics**

Role in thyroid cancer, 74-76  
Viral oncogenicity and, 358

## **Government, and cancer**

HEW studies on cost/effectiveness of second opinions, 363-364  
Research funding, 312-315  
Search for carcinogens, 239-240

## **H**

## **Hairy cell leukemia (HCL)**

Chemotherapy for, 276-277  
Diagnosis of,  
Clinical, 265-267  
Differential, 267-270, 272-274  
Morphologic, 266-270, 272-275  
Splenectomy for, 265, 269-270, 273-277

## **Head and neck cancers**

Management of,  
Following irradiation, 178-180  
(See also, Oral cancer)

## **Hemoccult test**

206-207, 217

## **Hodgkin's disease**

Relationship to chemotherapy, 57-59  
Treatment of,  
Stage III B disease, 117  
With MOPP and ABVD, 116-117

**Hormone therapy**

For prostate cancer, 110-114  
With DES and TACE, 181  
(See also, Endocrine therapy)

**Hospice approach**, to terminal cancer

Bereavement follow-up in, 234  
Characteristics of, 225, 230-231, 236  
Meeting emotional needs through, 226-227, 231  
Nursing care in, 232-234  
Pain control and, 227-229, 231  
United States hospices, 225, 229  
Calvary hospital, 235  
Hospice, Inc., 232

**Hyperthyroidism**

And cancer, 77-79  
Following  $^{131}\text{I}$  therapy, 81

**Hypophysectomy**

For metastatic breast cancer, 192  
For prostate cancer, 112

**I****Immunology**, and cancer

Assays of immune status, 106-108, 260-268  
Disorders of immune function, 78  
Test for immunocompetence, 61  
Following intravenous hyperalimentation, 329-330  
Treatment by,  
For neuroblastoma, 156

**Incidence rates**, cancer

In the elderly, 3-6  
Of thyroid cancer, 66-71  
Of soft tissue sarcomas, 284  
(See also, Statistics)

**Interferon**

Anti-viral effects of, 278-281  
For cancer treatment,  
Of non-Hodgkin's lymphoma, 280  
Of osteogenic sarcoma, 280  
Potential uses of, 280-283  
Production of, 281-282  
Types of, 279

**Interviews**

Clinical trials for cancer, 241-246  
Interferon and cancer treatment, 278-283  
Oral contraceptives and cancer, 118-123  
Problems in the pathologic interpretation of minimal cancer, 141-145  
Viruses and cancer, 356-361

**Intravenous hyperalimentation (IVH)**

As adjunct to,  
Chemotherapy, 324-326  
Radiotherapy, 326-328  
Surgery, 328-329  
Candidates for, 323  
Effects on tumor growth of, 322-323  
Management of fistulas by, 327-328  
Septic complications of, 328-330

**Intravenous pyelography**

For bladder cancer, 172  
For embryonal rhabdomyosarcoma, 158  
For neuroblastoma, 153-154  
For Wilms' tumor, 147-148

**Iodine deficiency**

In thyroid cancer, 76-77

**Ionizing radiation**

Effects of,  
On breast cancer, 83  
On thyroid cancer, 67-74

**J****Jones, Henry Bence**

Biography of, 47-48

**L****Leukemia**

Following chemotherapy, 57-59  
Treatment with Rubidazole, 62  
(See also, Hairy cell leukemia)

**Leukopenia**

Following irradiation, 60

**Leukoplakia**

Malignant potential of, 337  
In oral cancer, 297-300

**Life Extension Institute**

Study of proctosigmoidoscopy, 211-217

**Liver tumors**

Oral contraceptives and, 121-122

**Loeb, Leo**

Biography of, 367-368

**Looking at Cancer**, 60**Lung cancer**

Asbestos exposure and, 87, 91, 95  
Metastases of,  
In Wilms' tumor, 150-151

**Lymphangiography**

For embryonal rhabdomyosarcoma, 158, 286  
For prostate cancer, 108, 110  
Success in children, 60

**Lymph node dissection**

Role in prostate cancer, 108-110

**Lymphosarcoma cell leukemia**, 180-181**M****Mammography**

Use of,  
For minimal breast cancer, 144  
For nipple discharge, 134-135

**Mastectomy**

Breast reconstruction following,  
Advances in, 218-219  
Ineligibility for, 221  
Technique of, 220-224

**Mesothelioma**, 87-90

For synovial sarcoma, 162

**Minimal cancer**

Interpretation of, 141-145

**Mortality rates**

Leading causes of, 18-19, 32  
Of cancer,

Among Medicare recipients, 2  
In the elderly, 2-3, 5-6  
Probabilities, 33-46  
(See also, Statistics)

**Multiple endocrine adenomatosis**, 74, 82

**Multiple myeloma**

First description of, 47-56

**Multiple primary cancers**

Following chemotherapy, 58  
Of the breast and thyroid, 81-84

## N

**National Cancer Institute**

Cancer Morbidity Survey, 33-35  
Interferon Working Group, 283  
Third National Cancer Survey, 6, 66, 70  
Veterinary Medical Data Program, 79

**National Prostatic Cancer Task Force**, 105

Participants in, 113

**National Wilms' Tumor Study**, 149-151

**Nausea and vomiting**

Following chemotherapy, 194-196, 201  
Following irradiation, 195, 198  
Physiology of, 194-195  
Treatment of,  
By antiemetics, 194-200  
By antihistamines, 196-197

**Neuroblastoma**

Clinical presentations of, 152-153  
Prognosis of, 152  
Treatment of, 154-155

**Nipple discharge**, non-lactational  
And occult carcinoma, 133-135  
Localization of,  
By mammary duct injection, 296  
Treatment of, 134-138  
Surgical techniques in, 136-139  
Types of, 130-132

**Nitrogen mustards**

Rhoads' discussion concerning,  
Chemical properties of, 306  
Pharmacologic effects of, 307-312

**Nursing**, cancer

Hospice approach to, 232-234

**Nutritional therapy**, for cancer

(See, Intravenous hyperalimentation)

## O

**Old age**, and cancer

(See, Cancer in the elderly)

**Oophorectomy**

For metastatic breast cancer, 191

**Opinions**

Carcinogenic potential of  
chemotherapy, 57-59  
Controversy in direction of cancer research,  
312-315  
Critical look at "second opinions," 363-364  
False cancer claims, 124-126  
Government vs. carcinogens, 239-240

**Oral Cancer**

Dental management following irradiation for,  
178-180  
Erythroplasia and,  
High-risk sites for, 301-302  
Identification of, 299-302  
Types suggesting cancer, 299-300  
Leukoplakia and,  
Confusion in definition of, 298-299  
Incidence of malignant change in,  
297-298, 300  
Malnutrition in patients with, 328-329  
Mortality rates of, 297, 302  
In the elderly, 6

**Oral contraceptives**, and cancer, 118-123

**Orchiectomy**

Effects in metastatic breast cancer, 182-190  
For paratesticular rhabdomyosarcoma, 161

**Osteogenic sarcoma**

Treatment with interferon for, 280

**Ovarian cancer**

Endometrioid type of, 181

## P

**Paget's disease**, 178

Malignant potential of, 338

**Pain control**

Hospice approach to,  
Use of narcotics for, 227-229, 231

**Palliation**

For prostate cancer, 110-114  
Hospice approach to, 227-231

**Pap test**, 120-121, 202, 319

**Papanicolaou, George N.**

Stamp honoring, 164-169

**Papilloma**, bladder, 171, 173

**Paratesticular rhabdomyosarcoma**, 157-161

**Pathology**

Criteria for diagnosis of cancer by, 331  
Difficulty in establishing, 331-333

Dukes' classification of rectal cancer,  
249-255

For benign lesions that mimic cancer,

Examples of, 339-340

For precancerous lesions,

Evaluation of malignant potential in,  
Actinic keratosis, 338

Colorectal polyps, 335-336

Hutchinson's freckle, 336-337

Leukoplakia, 337

Paget's disease, 338

von Recklinghausen's disease, 338

Xeroderma pigmentosum, 336

Interpretation of minimal cancer by, 141-145

Need for clinical relevance of, 333-334

Of bladder cancer, 172

Of hairy cell leukemia, 265-270, 272-274

Of neuroblastoma, 151-152

Of soft tissue sarcomas, 284, 286-288

Embryonal rhabdomyosarcoma, 156-157

Of thyroid cancer, 70-74

Of Wilms' tumor, 146

**Polyps**

(See, Colorectal polyps)

**Precancerous lesions**

Malignant potential of,  
Actinic keratosis, 338  
Colorectal polyps, 335-336  
Gynecologic lesions, 338  
Hutchinson's freckle, 336-337  
Leukoplakia, 337  
Paget's disease, 338  
von Recklinghausen's disease, 338  
Xeroderma pigmentosum, 336  
Of the oral cavity, 297-302

**Proctosigmoidoscopy**

Life Extension Institute study of,  
In asymptomatic males,  
According to age, 212-217  
As a screening procedure, 214-217  
Detection of polyps by, 211-217  
(See also, Sigmoidoscopy)

**Prolactin**

Mammary cancer and, 83

**Prostate cancer**

Chemical assessment of,  
With acid phosphatase determinations,  
106-108, 258-264  
In blacks, 104  
In the elderly, 4-6  
National Prostatic Cancer Task Force,  
105, 261  
Staging of, 108-109  
Survival rates for, 105  
Treatment of,  
With chemotherapy, 112-114  
With hormones, 110-112, 114, 181  
With radiation, 60, 110-111, 181  
With surgery, 109-111

**R****Radiation therapy**

And resulting leukopenia, 60  
Care of head and neck following, 178-180  
Effects on thyroid cancer, 67-74, 79-81  
Fistula formation following, 327-328  
For bladder cancer, 173-177  
For neuroblastoma, 155  
For prostate cancer, 60, 110  
For soft tissue sarcomas, 287-292  
Embryonal rhabdomyosarcoma, 159  
For Wilms' tumor, 148-150  
Intravenous hyperalimentation as  
adjunct to, 326-327  
Nausea and vomiting following, 195, 198,  
326-327  
Pretreatment planning for,  
With CT scan, 100

**Radioimmunoassay (RIA)**

For prostatic acid phosphatase,  
106-107, 260-262

**Rectal cancer**

Dukes' classification of, 249-255  
Extent and types of metastases.  
Survival following, 249-255  
(See also, Colon and rectum cancer)

**Reporting on Cancer Research, 61-62****Research, cancer**

Controversy in direction of, 312-315  
Funding for, 313-314  
Status of oncogenic viruses and, 359

**Rhoads, Cornelius P.**

Biography of, 304-305

**Risk of cancer**

Asbestos exposure and, 87-99  
Following chemotherapy, 57-59  
Following irradiation in children, 79-81  
Probabilities of developing or dying of  
cancer, 33-46

**RNA**

Molecular hybridization, 61

**S****Sarcomas, soft tissue**

Botryoides variety of, 156-161  
Desmoid variety of, 294  
Diagnostic evaluation of, 285, 286  
With biopsy, 285-287  
Embryonal rhabdomyosarcoma, 156-161  
Fibrosarcoma, 161-162  
Histopathologic types of, 284, 286-287  
Staging of, 285, 289  
Synovial sarcoma, 162-163  
Treatment of,  
With chemotherapy, 292-294  
With combined approach, 285, 287,  
289-292  
With radiation alone, 288  
With surgery alone, 288-289

**Scans, for cancer**

In diagnosis of,  
Embryonal rhabdomyosarcoma, 158  
Wilms' tumor, 154  
<sup>99m</sup> Technetium pertechnetate, 80  
(See also, Computerized transaxial  
tomography)

**Sigmoidoscopy**

In women,  
Compared to breast and gynecologic  
exams, 202-210  
Walter Reed Medical Center study of,  
202-210  
(See also, Proctosigmoidoscopy)

**Skin cancer**

Precancerous lesions and,  
Actinic keratosis, 338  
Hutchinson's freckle, 336-337  
Xeroderma pigmentosum, 336

**Smoking, cigarette**

Bladder cancer and, 60  
Cancer deaths and, 240  
Effects of low tar and nicotine, 375-376  
Exposure to asbestos and, 95

**Solid-phase fluorescent immunoassay**

For prostatic acid phosphatase, 262-263

**Splenectomy**

For hairy cell leukemia, 265, 269-270,  
273-277

**Staging**

- Clinical vs. pathologic.
- In bladder cancer, 172-173
- Dukes',
  - Of rectal cancer, 249-255
  - Of prostatic cancer, 108-109
- Of soft tissue sarcomas, 285, 289
  - Embryonal rhabdomyosarcoma, 158-159
- Of Wilms' tumor, 148

**Stamps, cancer, 164-169****Statistics, cancer**

- Incidence,
  - By sex and site, 17, 24
  - By stage, 26
  - By state, 31
  - In children, 23
- In persons over 75 years old, 2-6
- Mortality,
  - Age-adjusted, 20-21
  - Around the world, 28
  - By sex and site, 17, 22, 25
- Risk of developing or dying of cancer, 33-46
- By site, 40-42
- Survival, 30

**Stilbestrol**

- For prostate cancer, 112

**Subareolar abscess, of the breast, 131-133****Surgery**

- En bloc excision,
  - Of major ducts in breast, 132-139
- For bladder cancer, 170-176
- For neuroblastoma, 154-155
- For soft tissue sarcomas, 287-292
  - Embryonal rhabdomyosarcoma, 159-161
  - Fibroma, 162
- Nephrectomy, 147-150
- Orchiectomy, 161, 182-190
- Prostatectomy, 109-110
- Splenectomy, 265, 269-270, 273-277

**Survival rates**

- For bladder cancer, 173-175
- For gastric cancer, 60
- For prostate cancer, 105
- Improvement in, 318-319
- (See also, Statistics)

**Synovial Sarcoma, 162-163****T****Taylor, Robert M.**

- Biography of, 127-128

**Terminal care, for cancer**

- Editorial on, 63-64, 256
- (See also, Hospice approach)

**Third National Cancer Survey, 6, 66, 70****Thyroid cancer**

- Association with iodine deficiency, 76-77
- Coincidence with Grave's disease, 77-79
- Effects of radiation on, 79-81
- Incidence patterns of, 66-72
- Induction with thyroid stimulating hormone, 74, 80, 83
- Pathology of, 70-74
- Relationship with breast cancer, 81-84
- Role of genetics in, 74-76
- Survival following, 72, 75-77

**Transplantation, of tumors, 369-374****U****Ultrasonography, 101****Urine**

- Analysis for proteinuria, 49-56
- Cytology of,
  - For bladder cancer, 170
- Determination of VMA and HVA in, 152-154

**Uterine cancer**

- Oral contraceptives and, 119
- Precancerous lesions and, 338

**V****Vincristine**

- For neuroblastoma, 155
- For soft tissue sarcomas, 294
  - Embryonal rhabdomyosarcoma, 159
- For Wilms' tumor, 148-151

**Viruses, and cancer**

- Cellular mechanisms of, 357
- Effects of interferon on, 279-283, 359-360
- Herpesviruses, 357-358
  - Cervical cancer and, 358
  - Epstein-Barr virus, 357-358
    - Treatment with ultraviolet light for, 360
- Multiple etiology theory of, 357
- Oncornaviruses, 358
- Vaccine for, 358-359

**Vomiting**

- (See, Nausea and Vomiting)

**von Recklinghausen's disease, 338****W****Wilms' tumor**

- Anaplastic variety of, 151
- Bilateral, 149-151
- Classification of, 148
- Diagnosis of, 146-148
- National Wilms' Tumor Study, 148-151
- Treatment of, 147-151

## Author Index, 1978

### Vol. 28, Nos. 1-6

#### A

Abels, J.C., 182-190  
Abramson, D.J., 202-210  
Abshier, W.M., 191  
Ackerman, L.V., 331-342

#### B

Bigongiari, L.R., 296  
Binder, S.C., 191-192  
Bodden, A., 33-46  
Buckles, R.G., 343-355

#### C

Cavalieri, L.F., 314-315  
Chu, T.M., 258-264  
Copeland, E.M., III, 322-330

#### D

Dukes, C.E., 249-255

#### E

Egeli, R.A., 130-140  
Exelby, P.R., 146-163

#### F

Farrow, J.H., 182-190  
Fisher, B., 241-246  
Friedman, R.M., 278-283

#### G

Garfinkel, L., 116, 297-303  
Gershman, S.T., 66-86  
Gohmann, J.T., 192  
Goldberg, S.M., 181  
Golomb, H.M., 265-277  
Grabstald, H., 181  
Gusberg, S.B., 181  
Guthrie, R.H., Jr., 218-224

#### H

Hammond, E.C., 87-99  
Hanlon, C.R., 363-366  
Harris, H.I., 238  
Harris, J.G., 194-201  
Holleb, A.I., 63-64, 127-128, 375-376  
Hutter, R.V.P., 141-145

#### J

Jones, H.B., 49-56

#### K

Karr, J., 258-264  
Kornfeld, D.S., 256  
Kretzschmar, R.M., 118-123

#### L

Lepley, J.B., 179-180  
Lew, E.A., 2-6  
Linman, J.W., 180-181  
Loeb, L., 369-374

#### M

Manning, G.C., 192  
Markel, W.M., 225-237  
Martin, D.S., 313-314  
Mashberg, A., 297-303  
Morton, P.C., 211-217  
Murphy, G.P., 104-115, 258-264

#### N

Nelson, J.H., Jr., 180

#### P

Pearl, S.S., 238  
Pickering, E.S., 316-320

#### R

Rapp, F., 356-361  
Raventos, A., 60  
Rhoads, C.P., 306-312  
Robbins, J.J., 362  
Rosai, J., 331-342  
Rosenberg, S.A., 117  
Rosner, F., 57-59

#### S

Samaan, N.A., 178  
Schottenfeld, D., 66-86  
Seidman, H., 33-46  
Selikoff, I.J., 87-99  
Shimkin, M.B., 61-62  
Silverberg, E., 17-46  
Sinon, V.B., 225-237  
Suit, H.D., 284-295

#### T

Taub, M., 164-169  
Treves, N., 182-190

#### U

Urban, J.A., 130-140, 296

#### V

Vardiman, J., 265-277

#### W

Watson, R.C., 100-103, 238  
Weisburger, J.H., 124-126  
Whelan, E.M., 239-240  
Whitmore, W.F., Jr., 170-177, 362  
Woodard, H.Q., 182-190

